About OptiBiotix Health
OptiBiotix Health is a company based in York (United Kingdom) founded in 2012. OptiBiotix Health offers products and services including SlimBiome, CholBiome, SweetBiotix, and WellBiome. OptiBiotix Health operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and Synlogic Therapeutics, among others.
- Headquarter York, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Optibiotix Health Plc
-
Annual Revenue
$1.09 M (USD)35.09as on Dec 31, 2024
-
Net Profit
-$2.26 M (USD)11.48as on Dec 31, 2024
-
EBITDA
-$2.58 M (USD)-38.59as on Dec 31, 2024
-
Latest Funding Round
$1.01 M (USD), Post-IPO
May 23, 2025
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OptiBiotix Health
OptiBiotix Health is a publicly listed company on the LSE with ticker symbol OPTI in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OptiBiotix Health
OptiBiotix Health offers a comprehensive portfolio of products and services, including SlimBiome, CholBiome, SweetBiotix, and WellBiome.
Supplement modulating microbiome for weight control and health improvement.
Product for managing cholesterol through microbiome effects.
Alternative sweetener influencing microbiome for better health outcomes.
Formulation enhancing overall wellbeing via microbiome modulation.
People of OptiBiotix Health
Unlock access to complete
Unlock access to complete
Funding Insights of OptiBiotix Health
Investors in OptiBiotix Health
OptiBiotix Health has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Seneca EIS Portfolio Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm
|
Locked | Locked | Locked |
Investor details for OptiBiotix Health
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OptiBiotix Health
Investment portfolio details for OptiBiotix Health
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OptiBiotix Health
Detailed financials for OptiBiotix Health
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Optibiotix Health Comparisons
Peer comparison for OptiBiotix Health
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OptiBiotix Health
OptiBiotix Health operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and Synlogic Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Engineered microbes are developed as programmable therapeutics for metabolic disorders.
|
|
| Locked | Locked | Locked |
Pendulum is focused on developing advanced probiotic solutions.
|
Detailed competitors of OptiBiotix Health
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Optibiotix Health
Complete news archive for OptiBiotix Health
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OptiBiotix Health
OptiBiotix Health was founded in 2012 and raised its 1st funding round 4 years after it was founded.
OptiBiotix Health is headquartered in York, United Kingdom.
Annual revenue of OptiBiotix Health is $1.09M as on Dec 31, 2024.
OptiBiotix Health was founded in 2012 in York, United Kingdom. Microbial strains are developed for addressing human metabolic diseases in the biotechnology sector. Proprietary platforms, including OptiScreen and OptiBiotic, are used to pinpoint metabolic pathways and compounds that influence human physiology. These strains serve as food ingredients, supplements, or active compounds for managing obesity, cholesterol and lipid distribution, and diabetes.
OptiBiotix Health's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
OptiBiotix Health offers SlimBiome, CholBiome, SweetBiotix, and WellBiome.
Yes, OptiBiotix Health is publicly traded on LSE under the ticker symbol OPTI.
OptiBiotix Health has 1 investor. Key investors include Seneca EIS Portfolio Fund.
The ticker symbol of OptiBiotix Health is OPTI on LSE.